SBIR-STTR Award

Ultrasound And Nerve Stimulator Guide
Award last edited on: 3/5/07

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$531,086
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Lawrence J Busse

Company Information

L J B Development

1101 St Gregory Street Suite 260
Cincinnati, OH 45202
   (513) 421-7444
   info@ljbdev.com
   www.ljbdev.com
Location: Single
Congr. District: 01
County: Hamilton

Phase I

Contract Number: 1R43GM057750-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1999
Phase I Amount
$99,639
Regional anesthesia (RA) is a powerful technique to reduce both perioperative and chronic pain. RA can provide significant benefits to patients since it requires only light sedation to accompany the regional blockade and thereby results in a low incidence of postoperative complications. In spite of its advantages, only 5-20% of patients eligible for RA receives this technique. Patient selection for RA depends primarily on a practitioner's confidence in applying the method. The proposed Phase 1 research is meant to develop a device, which will improve physician confidence by providing real-time feedback during RA. The success of the block depends on locating the deeply placed nerves for peripheral nerve blockade or the neurovascular bundle for plexus blockade. while avoiding surrounding vital structures. Since target nerves lie in close proximity to major blood vessels, guidance will be provided using a combination of Doppler ultrasound (for long-range direction) and electrical nerve stimulation for confirmation of needle placement. As part of this Phase I study, preliminary designs for ultrasound transducers, electrode patterns, materials, and construction methods will be identified. Successful completion of Phase I will lead to prototype development and testing during the Phase II portion of the project. PROPOSED COMMERCIAL APPLICATIONS: RA potentially benefits both patients and payers since its use promotes rapid recovery, shortened hospital stays and excellent pain control. The overall cost of RA is about 1/3 of costs associated with general anesthesia. The development of a disposable device for guiding RA will result in a commercially viable product, which will increase the use of RA and decrease the costs associated with surgical anesthesia and post-operative care

Phase II

Contract Number: 2R44GM057750-02A1
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2001
(last award dollars: 2002)
Phase II Amount
$431,447

Regional anesthesia (RA) is a powerful technique to reduce both perioperative and chronic pain. RA provides significant benefits to patients since it requires only light sedation and thereby results in a low incidence of postoperative complications. Despite these advantages, only 5-20 percent of eligible patients receives RA. Selection for RA depends primarily on a practitioner's confidence in applying the method. The proposed research will develop a device that will improve physician confidence by providing realtime feedback during RA. The success of the block: depends on locating the deeply placed nerves for peripheral nerve blockade or the neurovaseular bundle for plexus blockade, while avoiding surrounding vital structures. Since target nerves lie in close proximity to major blood vessels, guidance will be provided using a combination of Doppler ultrasound (for long-range direction) and electrical nerve stimulation for confirmation of needle placement. A Doppler Directed Nerve Stimulator (DDNS) using the continuous-wave Doppler method will be built and a clinical study undertaken to study its efficacy for guiding RA. A DDNS prototype using pulsed-wave Doppler will be built and tested for improved performance and safe about. Successful completion of Phase II will lead to the introduction of a new product for RA delivery. PROPOSED COMMERCIAL APPLICATION: RA potentially benefits both patients and payers since its use promotes rapid recovery, shortened hospital stays and excellent pain control. The overall cost of RA is about 1/3 of costs associated with general anesthesia. The development of a disposable device for guiding RA will result in a commercially viable product, which will increase the use of RA and decrease the costs associated with surgical anesthesia and post-operative care.